Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

December 19th 2024

Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

December 18th 2024

The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.

Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of Mirvetuximab Soravtansine in Ovarian Cancer

December 18th 2024

Ritu Salani, MD, discusses the role of mirvetuximab soravtansine in ovarian cancer and the need for specialist involvement in ocular toxicity management.

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

December 18th 2024

Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

December 18th 2024

Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.

Ultra-Sensitive Duplex Sequencing Improves Diagnostic Capabilities in Indolent Systemic Mastocytosis

December 17th 2024

Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.

Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials

December 17th 2024

Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

December 17th 2024

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT

December 13th 2024

Orca-T was retrospectively associated with improved OS in patients with high-risk hematologic malignancies undergoing allogeneic stem cell transplant.

MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis

December 13th 2024

Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

December 13th 2024

Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.

Pacritinib and Momelotinib Display Positive Real-World Impact on Anemia and Transfusion Needs in Myelofibrosis

December 12th 2024

Pacritinib and momelotinib both demonstrated favorable real-world effects on anemia and transfusion requirements among patients with myelofibrosis.

FDA Grants Fast Track Designation to IMM-1-104 in NRAS+ Advanced Melanoma

December 12th 2024

The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.

China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC

December 12th 2024

Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.

T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer

December 11th 2024

T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

December 11th 2024

Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.

Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden

December 11th 2024

Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET

December 11th 2024

NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma

December 10th 2024

Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL

December 10th 2024

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.